Search

Your search keyword '"Pérol, M"' showing total 48 results

Search Constraints

Start Over You searched for: Author "Pérol, M" Remove constraint Author: "Pérol, M" Database Academic Search Index Remove constraint Database: Academic Search Index
48 results on '"Pérol, M"'

Search Results

3. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.

8. 109P Treatment patterns in patients with advanced non-small cell lung cancer (aNSCLC) after discontinuing an immune checkpoint inhibitor (ICI) therapy in second-line or later in Germany and France.

9. Les traitements de maintenance dans les cancers bronchiques non à petites cellules métastatiques en 2012.

10. Treatment sequences in EGFR mutant advanced NSCLC.

12. Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation.

15. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

18. 1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial.

19. 1312P Datopotamab deruxtecan (Dato-DXd) vs docetaxel (DTX) in patients (pts) with advanced nonsquamous (NSQ) non-small cell lung cancer (NSCLC) with brain metastases (mets): Results from TROPION-Lung01.

20. 1259MO Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF).

21. LBA8 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeeR): A phase Ib/IIa clinical trial targeting identified resistance pathways.

22. 518MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs).

23. 509MO Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01.

24. LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01.

25. 1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A.

26. 1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02.

27. 1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs).

28. 79P Cell lineage context and type of genomic alteration predict for the therapeutic relevance of tyrosine kinase inhibitors in human cancers.

29. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.

31. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.

33. 976P Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01.

35. 1176P Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)

36. 1842P Molecular testing in older patients treated for an advanced or metastatic non-squamous non-small cell lung cancer.

37. Anti- PD1-induced psoriasis: a study of 21 patients.

38. MN/CA9: a potential gene marker for detection of malignant cells in effusions.

39. 1325P Long-term survival and health-related quality of life in patients treated with nivolumab for advanced non-small cell lung cancer: A wide prospective French real-world study (EVIDENS).

40. 1242P Characteristics of the first 615 patients enrolled in Pacific R: A study of the first real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.

41. Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer: A phase II trial conducted by the Groupe Français de Pneumo-Cancérologie (GFPC)

42. LBA53 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study.

46. Dramatic improvement after rituximab in a patient with paraneoplastic treatment-refractory Morvan syndrome associated with anti- CASPR2 antibodies.

47. Economic Impact of Centralized Histological Reviews in Patients with Sarcoma, Gist, and Desmoid Tumors.

48. Cost of Discordant Diagnoses in Sarcoma, Gist, and Desmoid Tumors in France: Results From the RREPS (Reseau De Reference En Pathologie Des Sarcomes) Network.

Catalog

Books, media, physical & digital resources